Please login to the form below

Not currently logged in
Email:
Password:

CSCC

This page shows the latest CSCC news and features for those working in and with pharma, biotech and healthcare.

As France protests, Sanofi takes axe to 670 jobs

As France protests, Sanofi takes axe to 670 jobs

dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.

Latest news

  • Dupixent helps put Sanofi back on growth track Dupixent helps put Sanofi back on growth track

    Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... Regeneron-partnered cemiplimab is the first of the

  • Sanofi’s PD-1 inhibitor starts EU review for skin cancer Sanofi’s PD-1 inhibitor starts EU review for skin cancer

    Sanofi has filed cemiplimab in the first instance as a treatment for advanced cutaneous squamous cell carcinoma (CSCC), which it says is the “deadliest form of non-melanoma skin cancer”. ... As of yet, none of the other PD-1/PD-L1-targeting drugs are

  • Sanofi/Regeneron start first filings for PD-1 drug cemiplimab Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

    CSCC is the second deadliest skin cancer after melanoma, and while quite treatable if caught early it is very serious in the advanced stages. ... Advanced CSCC is responsible for 3, 900 to 8, 800 deaths per year in the US,” said Regeneron’s clinical

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics